Combination of Gemcitabine and Cisplatin as First-Line Therapy in Advanced Non-Small-Cell Lung Cancer.
- Author:
Nam Su LEE
1
;
Jae Ho BYUN
;
Sang Byung BAE
;
Chan Kyu KIM
;
Kyu Taeg LEE
;
Sung Kyu PARK
;
Jong Ho WON
;
Dae Sik HONG
;
Hee Sook PARK
Author Information
1. Department of Internal Medicine, Soon Chun Hyang University College of Medicine, Seoul, Korea. parkhs@hosp.sch.ac.kr
- Publication Type:Original Article
- Keywords:
Non-small-cell lung cancer;
Chemotherapy;
Gemcitabine;
Cisplatin
- MeSH:
Cisplatin*;
Drug Therapy;
Drug Therapy, Combination;
Fatigue;
Follow-Up Studies;
Humans;
Lung Neoplasms*;
Lung*;
Mortality;
Neutropenia;
Prognosis;
Prospective Studies;
Quality of Life;
Thrombocytopenia
- From:Cancer Research and Treatment
2004;36(3):173-177
- CountryRepublic of Korea
- Language:English
-
Abstract:
PURPOSE: The prognosis of patients with advanced non-small-cell lung cancer (NSCLC) is extremely poor. Many prospective randomized trials on patients with advanced NSCLC suggested systemic chemotherapy improves both the survival and quality of life. A phase II trial was conducted to evaluate the efficacy and safety profile of the combination chemotherapy of gemcitabine and cisplatin in advanced NSCLC. MATERIALS AND METHODS: Forty-four patients with locally advanced or metastatic NSCLC were enrolled. The patients received a cisplatin, 75 mg/m(2), infusion over 30 minutes on days 1, followed by a gemcitabine, 1, 250 mg/m(2), infusion over 30 minutes on days 1 and 8 every 3 weeks. RESULTS: The median age of the patients was 64 years (range: 27~75). Forty-one patients were assessable for response and toxicity analyses. The overall response rate was 53.6%, but with no complete remissions. The median time to progression was 5.6 months (range: 1~15.4). The median survival was 14.2 months (95% confidence interval (CI), 13.8~22.5). A total of 179 cycles were administered, with a median of 4 cycles of chemotherapy, ranging from 2 to 9 cycles. The most common hematological toxicities were NCI grades 3/4 neutropenia (24%) and thrombocytopenia (7.8%). The most common non-hematological toxicity was fatigue (42.4%). There were no life-threatening toxicity or treatment related mortalities. The median duration of follow up was 9.4 months, ranging from 1.6 to 30.3 months. CONCLUSION: In this trial, the combination of gemcitabine and cisplatin showed significant activity, with acceptable and manageable toxicities as a first-line regimen for patients with advanced NSCLC.
